Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine
- PMID: 14662021
- PMCID: PMC11160295
- DOI: 10.1111/j.1349-7006.2003.tb01401.x
Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine
Abstract
Malignant rhabdoid tumor (MRT) has been considered to have multiphenotypic diversity characteristics. Some MRTs exhibit a neural phenotype. However, it is still unclear whether MRT cells can display a skeletal muscle, smooth muscle or smooth muscle-like cell phenotype, like those of pericytes and mesangial cells. To determine if MRTs exhibit skeletal muscle cell or smooth muscle-like cell phenotypes, six MRT cell lines (TM87-16, STM91-01, TTC549, TTC642, YAM-RTK1 and TTC1240) were examined for markers of skeletal muscle (MyoD, myogenin, myf-5, myf-6, acetylcholine receptor-alpha, -beta and -gamma), smooth muscle (alpha-smooth muscle actin, SM-1 and SM22), and smooth muscle-like cells, such as pericytes (angiopoietin-1 and -2) and mesangial cells (megsin), using conventional RT-PCR, semi-quantitative PCR, western blotting and immunocytochemistry before and after differentiation-induction with 5-azacytidine. alpha-Smooth muscle actin and SM22 were detected in all six MRT cell lines, while MyoD and myf-5, crucial markers for skeletal myogenic determination, were not. The TM87-16 cell line expressed SM-1 and angiopoietin-1. TTC1240 also expressed angiopoietin-1. Interestingly, STM91-01 expressed megsin, a novel marker for mesangial cells, in addition to angiopoietin-1. Our results indicated that some MRTs exhibited smooth muscle and/or smooth muscle-like cell phenotypes and some renal MRTs might be of mesangial origin. Recently, smooth muscle and also smooth muscle-like cells have been considered to be of neuroectodermal origin. MRT can thus considered to belong to the category of primitive neuroectodermal tumors (PNETs) in the broad sense.
References
-
- Wick MR, Ritter JH, Dehner LP. Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. Semin Diagn Pathol 1995; 12: 233–48. - PubMed
-
- Ogino S, Ro JY, Redline RW. Malignant rhabdoid tumor: a phenotype? An entity?—a controversy revisited. Adv Anat Pathol 2000; 7: 181–90. - PubMed
-
- Ota S, Crabbe DCG, Tran TN, Triche TJ, Shimada H. Malignant rhabdoid tumor: a study with two established cell lines. Cancer 1993; 71: 2862–72. - PubMed
-
- Garcia‐Bustinduy M, Alvarez‐Arguelles H, Guimera F, Garcia‐Castro C, Sanchez‐Gonzalez R, Hernandez N, Diaz‐Flores L, Garcia‐Montelongo R. Malignant rhabdoid tumor beside benign skin mesenchymal neoplasm with myofibromatous features. J Cutan Pathol 1999; 26: 509–15. - PubMed
-
- Bergmann M, Sppaar HJ, Ebhard G, Masini T, Edel G, Gullotta F, Meyer H. Primary malignant rhabdoid tumours of the central nervous system: an immunohistochemical and ultrastructural study. Acta Neurochir 1997; 139: 961–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
